Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 7
Submit an article Journal homepage
1,651
Views
28
CrossRef citations to date
0
Altmetric
Original Research

Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma

Xinqi WuDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MAORCID Iconhttp://orcid.org/0000-0003-4979-4596 http://orcid.org/0000-0003-4979-4596 http://orcid.org/0000-0003-4979-4596View further author information
ORCID Icon ORCID Icon ORCID Icon,
Anita Giobbie-HurderCenter for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MAView further author information
,
Erin M. ConnollyDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MAView further author information
,
Jingjing LiDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MAView further author information
,
Xiaoyun LiaoDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MAView further author information
,
Mariano SevergniniDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MAORCID Iconhttp://orcid.org/0000-0001-6783-8500View further author information
ORCID Icon,
Jun ZhouDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MAView further author information
,
Scott RodigDepartment of Pathology Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MAView further author information
&
F. Stephen HodiDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MACorrespondence[email protected]
View further author information
 show all
Article: e1440930 | Received 22 Nov 2017, Accepted 10 Feb 2018, Published online: 13 Mar 2018

Citations (28)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer & Erika Vacchelli. (2020) Trial watch: IDO inhibitors in cancer therapy. OncoImmunology 9:1.
Read now
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer & Erika Vacchelli. (2020) Trial watch: TLR3 agonists in cancer therapy. OncoImmunology 9:1.
Read now
Melody Smith, Elena García-Martínez, Michael R. Pitter, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Toll-like receptor agonists in cancer immunotherapy. OncoImmunology 7:12.
Read now
Jonathan G. Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Boeuf, Derek R. Clements, Jean-Eudes Fahrner, Laetitia Fend, John C. Bell, Karen L. Mossman, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology 7:12.
Read now

Articles from other publishers (24)

Saba Tabasum, Dinesh Thapa, Anita Giobbie-Hurder, Jason L. Weirather, Marco Campisi, Pieter J. Schol, Xiaoyu Li, Jingjing Li, Charles H. Yoon, Michael P. Manos, David A. Barbie & F. Stephen Hodi. (2023) EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade. Cancer Immunology Research 11:11, pages 1493-1507.
Crossref
Gunjan Dagar, Ashna Gupta, Tariq Masoodi, Sabah Nisar, Maysaloun Merhi, Sheema Hashem, Ravi Chauhan, Manisha Dagar, Sameer Mirza, Puneet Bagga, Rakesh Kumar, Ammira S. Al-Shabeeb Akil, Muzafar A. Macha, Mohammad Haris, Shahab Uddin, Mayank Singh & Ajaz A. Bhat. (2023) Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. Journal of Translational Medicine 21:1.
Crossref
Wenli Yang, Yanyang Pang, Xi Wang, Zhiheng Lai, Yanda Lu, Shaojiang Zheng & Wu Wang. (2023) A novel CTLA-4 blocking strategy based on nanobody enhances the activity of dendritic cell vaccine-stimulated antitumor cytotoxic T lymphocytes. Cell Death & Disease 14:7.
Crossref
Chan Li, Sheng Zhou, Chuncheng Chen, Lijun Zhu, Shijie Li, Zhuoyue Song, Jian Liang, Chunzhi Tang, Nenggui Xu, Tao Liu & Shihui Liu. (2023) DDTC-Cu(I) based metal-organic framework (MOF) for targeted melanoma therapy by inducing SLC7A11/GPX4-mediated ferroptosis. Colloids and Surfaces B: Biointerfaces 225, pages 113253.
Crossref
Lee Seng Lau, Norhan B. B. Mohammed & Charles J. Dimitroff. (2022) Decoding Strategies to Evade Immunoregulators Galectin-1, -3, and -9 and Their Ligands as Novel Therapeutics in Cancer Immunotherapy. International Journal of Molecular Sciences 23:24, pages 15554.
Crossref
Margaret M. Cocks & Anne M. Mills. (2022) The Immune Checkpoint Inhibitor LAG-3 and Its Ligand GAL-3 in Vulvar Squamous Neoplasia. International Journal of Gynecological Pathology 41:2, pages 113-121.
Crossref
Wu Wang, Xi Wang, Wenli Yang, Kai Zhong, Na He, Xuexia Li, Yanyang Pang, Zi Lu, Aiqun Liu & Xiaoling Lu. (2021) A CTLA-4 blocking strategy based on Nanobody in dendritic cell-stimulated cytokine-induced killer cells enhances their anti-tumor effects. BMC Cancer 21:1.
Crossref
Diego José Laderach & Daniel Compagno. (2021) Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure. Cancers 13:18, pages 4529.
Crossref
Qiu-Yang Jin, Ying-Shuang Li, Xing-Hui Qiao, Jia-Wei Yang & Xiu-Li Guo. (2021) Targeting galectins in T cell-based immunotherapy within tumor microenvironment. Life Sciences 277, pages 119426.
Crossref
Ramiro M. Perrotta, Camila A. Bach, Mariana Salatino & Gabriel A. Rabinovich. (2021) Reprogramming the tumor metastasis cascade by targeting galectin-driven networks. Biochemical Journal 478:3, pages 597-617.
Crossref
Weifeng Ren, Xiaomeng Cai, Jun Chen, Lifo Ruan, Huiru Lu, Jiayu Zhang, Yi Hu & Jimin Gao. (2021) GM-CSF-Loaded Nanoparticles for Photothermal-Assisted Immunotherapy against Orthotopic Bladder Cancer. Oncologie 23:3, pages 359-371.
Crossref
Pilar Navarro, Neus Martínez-Bosch, Ada G. Blidner & Gabriel A. Rabinovich. (2020) Impact of Galectins in Resistance to Anticancer Therapies. Clinical Cancer Research 26:23, pages 6086-6101.
Crossref
Elisa Peranzoni, Vincenzo Ingangi, Elena Masetto, Laura Pinton & Ilaria Marigo. (2020) Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade. Frontiers in Immunology 11.
Crossref
Chisa Shimada, Rui Xu, Linah Al-Alem, Marina Stasenko, David R. Spriggs & Bo R. Rueda. (2020) Galectins and Ovarian Cancer. Cancers 12:6, pages 1421.
Crossref
Daniel Compagno, Carolina Tiraboschi, José Daniel Garcia, Yorfer Rondón, Enrique Corapi, Carla Velazquez & Diego José Laderach. (2020) Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials. Biomolecules 10:5, pages 750.
Crossref
Lisa A. Friedman, Kari L. Ring & Anne M. Mills. (2020) LAG-3 and GAL-3 in Endometrial Carcinoma: Emerging Candidates for Immunotherapy. International Journal of Gynecological Pathology 39:3, pages 203-212.
Crossref
Shuzhen Tan, Dongpei Li & Xiao Zhu. (2020) Cancer immunotherapy: Pros, cons and beyond. Biomedicine & Pharmacotherapy 124, pages 109821.
Crossref
María Romina Girotti, Mariana Salatino, Tomás Dalotto-Moreno & Gabriel A. Rabinovich. (2020) Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression. Journal of Experimental Medicine 217:2.
Crossref
Douglas DonnellyIIIIII, Phyu P. Aung & George Jour. (2019) The “-OMICS” facet of melanoma: Heterogeneity of genomic, proteomic and metabolomic biomarkers. Seminars in Cancer Biology 59, pages 165-174.
Crossref
Rebecca C. Gilson, Sachith D. Gunasinghe, Ludger Johannes & Katharina Gaus. (2019) Galectin-3 modulation of T-cell activation: mechanisms of membrane remodelling. Progress in Lipid Research 76, pages 101010.
Crossref
Anliang Xia, Yan Zhang, Jiang Xu, Tailang Yin & Xiao-Jie Lu. (2019) T Cell Dysfunction in Cancer Immunity and Immunotherapy. Frontiers in Immunology 10.
Crossref
M Nyakas, E Aamdal, K D Jacobsen, T K Guren, S Aamdal, K T Hagene, P Brunsvig, A Yndestad, B Halvorsen, K A Tasken, P Aukrust, G M Mælandsmo & T Ueland. (2019) Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma. Clinical and Experimental Immunology 197:1, pages 74-82.
Crossref
Meenal Datta, Lisa M. Coussens, Hiroyoshi Nishikawa, F. Stephen Hodi & Rakesh K. Jain. (2019) Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. American Society of Clinical Oncology Educational Book:39, pages 165-174.
Crossref
Marina Martinez & Edmund Kyung Moon. (2019) CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Frontiers in Immunology 10.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.